Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 3/20 | 0.47 |
| ▸ | CDYL2 | Q8N8U2 | 3/20 | 0.45 |
| ▸ | CDYL | Q9Y232 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | CBX7 | O95931 | 1/20 | 0.42 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ALPG | P10696 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.40 |
| ▸ | TPO | P07202 | 1/20 | 0.40 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11161652 | 0.88 | TMEM97 (0.54) | NPY5RTMEM97SIGMAR1 | |
| SCHEMBL11107436 | 0.87 | NPY5R (0.47) | NPY5RCDYL2CDYLMAPTTP53 | |
| SCHEMBL2407440 | 0.82 | SIGMAR1 (0.50) | CDYL2CDYLMAPTCBX7CDY1; CDY1B | |
| SCHEMBL2361576 | 0.82 | CDYL2 (0.45) | CDYL2CDYLTP53CBX7CDY1; CDY1B | |
| SCHEMBL2360116 | 0.82 | CDYL2 (0.45) | CDYL2CDYLMAPTTP53CBX7 | |
| Hydrochloric Acid SCHEMBL10545731 | 0.79 | GAA (0.51) | NPY5RTP53NPSR1TDP1 | |
| SCHEMBL2332474 | 0.78 | L3MBTL1 (0.60) | MAPTTP53L3MBTL1ALDH1A1NPSR1 | |
| SCHEMBL11038312 | 0.78 | MAPT (0.48) | NPY5RMAPTTP53TMEM97ALDH1A1 | |
| SCHEMBL2403057 | 0.78 | CDYL2 (0.64) | CDYL2CDYLCBX7CDY1; CDY1BALDH1A1 | |
| SCHEMBL10549857 | 0.77 | NPY5R (0.51) | NPY5RNPSR1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230277501-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| US-20230033195-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2023-02-02 | — | — | US | disclosed |
| US-20220265685-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2022-08-25 | — | — | US | disclosed |
| US-11160785-B2 | Methods and compositions for improving cognitive function | AGENEBIO INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20210244709-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2021-08-12 | — | — | US | disclosed |
| EP-3827820-A1 | BRIVARACETAM FOR IMPROVING COGNITIVE FUNCTION | The Johns Hopkins University (US) | 2021-06-02 | — | — | EP | disclosed |
| US-10806717-B2 | Methods and compositions for improving cognitive function | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-10-20 | — | — | US | disclosed |
| US-10624875-B2 | Methods and compositions for treating schizophrenia | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-04-21 | — | — | US | disclosed |
| EP-3610890-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA | The Johns Hopkins University (US) | 2020-02-19 | — | — | EP | disclosed |
| US-10154988-B2 | Methods and compositions for treating schizophrenia | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-12-18 | — | — | US | disclosed |
| US-20110212928-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-09-01 | — | — | US | disclosed |
| WO-2011100373-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-08-18 | — | — | WO | disclosed |
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | UCB PHARMA, S.A. (BE) | 2010-09-02 | — | — | US | disclosed |
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | UCB PHARMA, S.A. (BE) | 2010-09-02 | — | — | US | disclosed |
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | UCB PHARMA, S.A. (BE) | 2010-09-02 | — | — | US | disclosed |
| EP-2152262-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB Pharma, S.A. (BE) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008132142-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB PHARMA S.A. (BE) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008132142-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB PHARMA S.A. (BE) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008132139-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB PHARMA S.A. (BE) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008132139-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB PHARMA S.A. (BE) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10806717-B2 | Methods and compositions for improving cognitive function | GRIN2A, CHRNA2, SYNGR2 | NPY5R 3014/4885CDYL2 339/4885CDYL 1611/4885 |
| US-10154988-B2 | Methods and compositions for treating schizophrenia | RAB2A, SYNGR2, GRIN2A | NPY5R 1088/4885CDYL2 971/4885CDYL 2385/4885 |
| US-20210244709-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GRIN2A, CHRNA2, SYNGR2 | NPY5R 3014/4885CDYL2 339/4885CDYL 1611/4885 |
| US-11160785-B2 | Methods and compositions for improving cognitive function | BACE2, BACE1, GRIN2A | NPY5R 2402/4885CDYL2 1832/4885CDYL 3482/4885 |
| US-10624875-B2 | Methods and compositions for treating schizophrenia | RAB2A, SYNGR2, GRIN2A | NPY5R 694/4885CDYL2 478/4885CDYL 1285/4885 |
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | CNR2, CNR1, SLC18A2 | NPY5R 163/4885CDYL2 2678/4885CDYL 2832/4885 |
| US-20230277501-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GRIN2A, CHRNA2, SYNGR2 | NPY5R 3014/4885CDYL2 339/4885CDYL 1611/4885 |
| US-20220265685-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE1, BACE2, ACHE | NPY5R 3992/4885CDYL2 3071/4885CDYL 4362/4885 |
| US-20110212928-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE1, BACE2, ACHE | NPY5R 3992/4885CDYL2 3071/4885CDYL 4362/4885 |
| US-20230033195-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GRIN2D, GRIN2A, SLC18A2 | NPY5R 3395/4885CDYL2 2361/4885CDYL 4273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.